Protocol Ledger

NCT03596866 · Phase III · COMPLETED

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT03596866 sponsored by Takeda in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-19 Enrollment: 248 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03596866
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)248 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03596866
Protocol FieldVerified Registry Value
NCT IdentifierNCT03596866
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment248 participants (ACTUAL)
Registered Start Date2019-04-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03596866
Hospital Research SiteLocationSite Profile
Virginia Cancer SpecialistsFairfax, VAOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI